We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Haemonetics (HAE - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Haemonetics is a member of our Medical group, which includes 1095 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Haemonetics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for HAE's full-year earnings has moved 7.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, HAE has gained about 10.9% so far this year. Meanwhile, the Medical sector has returned an average of -8.2% on a year-to-date basis. This means that Haemonetics is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Amneal Pharmaceuticals (AMRX - Free Report) . The stock has returned 118.1% year-to-date.
The consensus estimate for Amneal Pharmaceuticals' current year EPS has increased 12.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Haemonetics belongs to the Medical - Products industry, which includes 95 individual stocks and currently sits at #89 in the Zacks Industry Rank. On average, stocks in this group have lost 8.2% this year, meaning that HAE is performing better in terms of year-to-date returns.
In contrast, Amneal Pharmaceuticals falls under the Medical - Drugs industry. Currently, this industry has 193 stocks and is ranked #89. Since the beginning of the year, the industry has moved -11.7%.
Investors interested in the Medical sector may want to keep a close eye on Haemonetics and Amneal Pharmaceuticals as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Haemonetics (HAE) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Haemonetics (HAE - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Haemonetics is a member of our Medical group, which includes 1095 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Haemonetics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for HAE's full-year earnings has moved 7.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, HAE has gained about 10.9% so far this year. Meanwhile, the Medical sector has returned an average of -8.2% on a year-to-date basis. This means that Haemonetics is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Amneal Pharmaceuticals (AMRX - Free Report) . The stock has returned 118.1% year-to-date.
The consensus estimate for Amneal Pharmaceuticals' current year EPS has increased 12.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Haemonetics belongs to the Medical - Products industry, which includes 95 individual stocks and currently sits at #89 in the Zacks Industry Rank. On average, stocks in this group have lost 8.2% this year, meaning that HAE is performing better in terms of year-to-date returns.
In contrast, Amneal Pharmaceuticals falls under the Medical - Drugs industry. Currently, this industry has 193 stocks and is ranked #89. Since the beginning of the year, the industry has moved -11.7%.
Investors interested in the Medical sector may want to keep a close eye on Haemonetics and Amneal Pharmaceuticals as they attempt to continue their solid performance.